Table of Contents

company-logo

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

Alphamab Oncology Dividend Announcement

• Alphamab Oncology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Alphamab Oncology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Alphamab Oncology Dividend History

Alphamab Oncology Dividend Yield

Alphamab Oncology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Alphamab Oncology stock? Use our calculator to estimate your expected dividend yield:

Alphamab Oncology Financial Ratios

P/E ratio-17.24
PEG ratio2.69
P/B ratio2.28
ROE-13.06%
Payout ratio0.00%
Current ratio4.61
Quick ratio4.42
Cash Ratio3.30

Alphamab Oncology Dividend FAQ

Does Alphamab Oncology stock pay dividends?
Alphamab Oncology does not currently pay dividends to its shareholders.
Has Alphamab Oncology ever paid a dividend?
No, Alphamab Oncology has no a history of paying dividends to its shareholders. Alphamab Oncology is not known for its dividend payments.
Why doesn't Alphamab Oncology pay dividends?
There are several potential reasons why Alphamab Oncology would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Alphamab Oncology ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Alphamab Oncology has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Alphamab Oncology a dividend aristocrat?
Alphamab Oncology is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Alphamab Oncology a dividend king?
Alphamab Oncology is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Alphamab Oncology a dividend stock?
No, Alphamab Oncology is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Alphamab Oncology stocks?
To buy Alphamab Oncology you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Alphamab Oncology stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.